

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	12468535
<b>Application Number:</b>	10594473
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	9501
<b>Title of Invention:</b>	Process for Preparing a Medicament
<b>First Named Inventor/Applicant Name:</b>	Xian-Ming Zeng
<b>Customer Number:</b>	23122
<b>Filer:</b>	Christopher R. Lewis/Lisa Bennett
<b>Filer Authorized By:</b>	Christopher R. Lewis
<b>Attorney Docket Number:</b>	TEVE-124US
<b>Receipt Date:</b>	04-APR-2012
<b>Filing Date:</b>	13-NOV-2007
<b>Time Stamp:</b>	16:03:36
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$930
RAM confirmation Number	2930
Deposit Account	180350
Authorized User	LEWIS,CHRISTOPHER R.

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	TEVE124US_RCETrans.pdf	697814 819359a52a1225b6b3ca40a814b8caf1e61 157c3	no	3

**Warnings:****Information:**

2		TEVE124US_IDS.pdf	189855 8b44d29f7aded60b99ca51ceede2f7ad2ef8 407c	yes	4
---	--	-------------------	--	-----	---

**Multipart Description/PDF files in .zip description****Document Description**      **Start**      **End**

Transmittal Letter      1      2

Information Disclosure Statement (IDS) Form (SB08)      3      4

**Warnings:****Information:**

3	Foreign Reference	WO2004017918.pdf	751190 622ec7d9b1dab6b9ecb452d973481ca4e4 868a98	no	15
---	-------------------	------------------	--	----	----

**Warnings:****Information:**

4	Foreign Reference	WO9500128.pdf	1326026 19ed7b1542f27eaa1896e327bf7981ebbe9 6f63f	no	33
---	-------------------	---------------	---	----	----

**Warnings:****Information:**

5	Non Patent Literature	BEGATetal.pdf	2432242 0056de923492b5860e9fc05583a04bea36 ba4bc	no	14
---	-----------------------	---------------	--	----	----

**Warnings:****Information:**

6	Non Patent Literature	IKEGAMletal_290.pdf	935577 59dee90e332b014ed38d7b4eb18c0182f0e 1f122	no	15
---	-----------------------	---------------------	--	----	----

**Warnings:****Information:**

7	Non Patent Literature	IKEGAMletal_323.pdf	460841 795875a7fb4b9c9c60049469fe7cfba783b a455	no	10
---	-----------------------	---------------------	---	----	----

**Warnings:****Information:**

8	Non Patent Literature	DEVILLIERSetal.pdf	311933 f1a54bbb8f41960df275b13f0fa4d32b6874 1638	no	7
---	-----------------------	--------------------	--	----	---

**Warnings:**

**Information:**

9	Non Patent Literature	CARTILIERetal.pdf	411861 d116ec3864864cd7d9da869dbb7cc3b4c3 40546d	no	16
---	-----------------------	-------------------	--	----	----

**Warnings:**

**Information:**

10	Non Patent Literature	OppnStatement_AstraZeneca.pdf	568841 3897cbc559036fc4bcd4a996ae081692e0f /ded	no	10
----	-----------------------	-------------------------------	---	----	----

**Warnings:**

**Information:**

11	Non Patent Literature	StmntofFacts_VecturaLimited.pdf	465519 bc349ff148e7a2eff2a850920bee194ceea5b b87	no	12
----	-----------------------	---------------------------------	--	----	----

**Warnings:**

**Information:**

12	Non Patent Literature	RODRIGUEZ_VAZQUEZetal.pdf	641717 2491b6e7596b963d44655458e6c351fce6 32f43	no	4
----	-----------------------	---------------------------	---	----	---

**Warnings:**

**Information:**

13		TEVE124US_Amend.pdf	316050 d583fcadad8c657289dc59d27c4d57d0d681 12e85	yes	8
----	--	---------------------	---	-----	---

**Multipart Description/PDF files in .zip description**

	Document Description	Start	End
	Amendment Submitted/Entered with Filing of CPA/RCE	1	1
	Claims	2	3
	Applicant Arguments/Remarks Made in an Amendment	4	8

**Warnings:**

**Information:**

14	Fee Worksheet (SB06)	fee-info.pdf	30447 8f92f8854b7b6820a8d40f8381d82854163 d874e	no	2
----	----------------------	--------------	---	----	---

**Warnings:**

**Information:**

<b>Total Files Size (in bytes):</b>	9539913
-------------------------------------	---------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.